ena-STUDY-Universita degli studi di Milano-02-01-2017-16:36:29:170-749
EFFECT OF L. CASEI DG® (LACTOBACILLUS PARACASEI CNCM I-1572) IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER PILOT STUDY.
We conducted a multicentre, randomized, double-blind, crossover, eighteen-week, placebo-controlled, pilot trial assessing the effect of L. casei DG® (Enterolactis plus®) on gut microbiota composition in patients with irritable bowel syndrome (IBS).
We conducted a multicentre, randomized, double-blind, crossover, eighteen-week, placebo-controlled, pilot trial assessing the effect of L. casei DG® (Enterolactis plus®) on gut microbiota composition in patients with irritable bowel syndrome (IBS).